20
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          No data is available on the molecular background of the extra-nodal extension (ENE) of lymph node metastasis (LN) in colorectal cancer (CRC).

          Methods

          A series of 22 ENE-positive CRCs was considered and three samples per case were selected (the primary CRC, an ENE-negative and an ENE-positive metastatic LN). Samples (n = 66) were analysed by immunohistochemistry for PD-L1, CD4, CD8, CD68 and CD80. Fifteen out of twenty-two cases were further profiled through a hotspot multigene mutational custom panel, including 164 hotspot regions of AKT1, APC, BRAF, CTNNB1, KIT, KRAS, NRAS, PDGFRA, PIK3CA, PTEN and TP53 genes.

          Results

          A significantly higher percentage of CD4-, CD8- and CD68-positive cells was observed at the invasive front of both CRCs and in ENE in contrast with what observed at the core of both CRCs and their matched nodal metastases. ENE was also characterized by a significantly higher number of CD80-positive cells. No significant difference was observed in PD-L1 distribution among the different specimens. Fourteen out of 15 CRCs (93%) showed at least a driver mutation. The most frequently mutated gene was TP53 (n = 8 tumors), followed by APC (n = 6), BRAF (n = 4), KRAS, NRAS and PIK3CA (n = 2). In 11 out of 15 CRCs (73%) the mutational profiling of the primary tumor was consistent with what obtained from the two matched LNs.

          Conclusions

          A heterogeneous intratumor immune-microenvironment has been observed in ENE-positive CRCs, which are characterized by an increased leukocytic infiltration at the ENE invasive front.

          Related collections

          Most cited references35

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Metabolic reprogramming: the emerging concept and associated therapeutic strategies

          Go Yoshida (2015)
          Tumor tissue is composed of cancer cells and surrounding stromal cells with diverse genetic/epigenetic backgrounds, a situation known as intra-tumoral heterogeneity. Cancer cells are surrounded by a totally different microenvironment than that of normal cells; consequently, tumor cells must exhibit rapidly adaptive responses to hypoxia and hypo-nutrient conditions. This phenomenon of changes of tumor cellular bioenergetics, called “metabolic reprogramming”, has been recognized as one of 10 hallmarks of cancer. Metabolic reprogramming is required for both malignant transformation and tumor development, including invasion and metastasis. Although the Warburg effect has been widely accepted as a common feature of metabolic reprogramming, accumulating evidence has revealed that tumor cells depend on mitochondrial metabolism as well as aerobic glycolysis. Remarkably, cancer-associated fibroblasts in tumor stroma tend to activate both glycolysis and autophagy in contrast to neighboring cancer cells, which leads to a reverse Warburg effect. Heterogeneity of monocarboxylate transporter expression reflects cellular metabolic heterogeneity with respect to the production and uptake of lactate. In tumor tissue, metabolic heterogeneity induces metabolic symbiosis, which is responsible for adaptation to drastic changes in the nutrient microenvironment resulting from chemotherapy. In addition, metabolic heterogeneity is responsible for the failure to induce the same therapeutic effect against cancer cells as a whole. In particular, cancer stem cells exhibit several biological features responsible for resistance to conventional anti-tumor therapies. Consequently, cancer stem cells tend to form minimal residual disease after chemotherapy and exhibit metastatic potential with additional metabolic reprogramming. This type of altered metabolic reprogramming leads to adaptive/acquired resistance to anti-tumor therapy. Collectively, complex and dynamic metabolic reprogramming should be regarded as a reflection of the “robustness” of tumor cells against unfavorable conditions. This review focuses on the concept of metabolic reprogramming in heterogeneous tumor tissue, and further emphasizes the importance of developing novel therapeutic strategies based on drug repositioning.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Overview of the 8th Edition TNM Classification for Head and Neck Cancer.

            The main purpose of the TNM system is to provide an anatomic-based classification to adequately depict cancer prognosis. Accurate cancer staging is important for treatment selection and outcome prediction, research design, and cancer control activities. To maintain clinical relevance, periodical updates to TNM are necessary. The recently published 8th edition TNM classification institutes the following changes to the staging of head and neck (excluding thyroid cancer): new stage classifications [HPV-related oropharyngeal cancer (HPV+ OPC) and soft tissue sarcoma of the head and neck (HN-STS)] and modification of T and N categories [T and N categories for nasopharyngeal cancer (NPC), T categories for oral cavity squamous cell carcinomas (OSCC), N categories for non-viral related head and neck cancer and unknown primary (CUP), and T categories for head and neck cutaneous carcinoma]. These changes reflect better understanding tumor biology and clinical behavior (e.g., HPV+ OPC and HN-STS), improved outcomes associated with technical advances in diagnosis and treatment (e.g., NPC), evolving knowledge about additional prognostic factors and risk stratification from research and observation (e.g., inclusion of depth of invasion variable for OSCC, inclusion of extranodal extension variable for all non-viral head and neck cancer, and reintroduction of size criteria for non-Merkel cell cutaneous carcinoma of the head and neck). This review summarizes the changes and potential advantages and limitations/caveats associated with them. Further evidence is needed to evaluate whether these changes would result in improvement in TNM stage performance to better serve the needs for clinical care, research, and cancer control.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Emerging roles of Myc in stem cell biology and novel tumor therapies

              Go Yoshida (2018)
              The pathophysiological roles and the therapeutic potentials of Myc family are reviewed in this article. The physiological functions and molecular machineries in stem cells, including embryonic stem (ES) cells and induced pluripotent stem (iPS) cells, are clearly described. The c-Myc/Max complex inhibits the ectopic differentiation of both types of artificial stem cells. Whereas c-Myc plays a fundamental role as a “double-edged sword” promoting both iPS cells generation and malignant transformation, L-Myc contributes to the nuclear reprogramming with the significant down-regulation of differentiation-associated genetic expression. Furthermore, given the therapeutic resistance of neuroendocrine tumors such as small-cell lung cancer and neuroblastoma, the roles of N-Myc in difficult-to-treat tumors are discussed. N-Myc-driven neuroendocrine tumors tend to highly express NEUROD1, thereby leading to the enhanced metastatic potential. Importantly enough, accumulating evidence strongly suggests that c-Myc can be a promising therapeutic target molecule among Myc family in terms of the biological characteristics of cancer stem-like cells (CSCs). The presence of CSCs leads to the intra-tumoral heterogeneity, which is mainly responsible for the therapeutic resistance. Mechanistically, it has been shown that Myc-induced epigenetic reprogramming enhances the CSC phenotypes. In this review article, the author describes two major therapeutic strategies of CSCs by targeting c-Myc; Firstly, Myc-dependent metabolic reprogramming is closely related to CD44 variant-dependent redox stress regulation in CSCs. It has been shown that c-Myc increases NADPH production via enhanced glutaminolysis with a finely-regulated mechanism. Secondly, the dormancy of CSCs due to FBW7-depedent c-Myc degradation pathway is also responsible for the therapeutic resistance to the conventional anti-tumor agents, the action points of which are largely dependent on the operation of the cell cycle. That is why the loss-of-functional mutations of FBW7 gene are expected to trigger “awakening” of dormant CSCs in the niche with c-Myc up-regulation. Collectively, although the further research is warranted to develop the effective anti-tumor therapeutic strategy targeting Myc family, we cancer researchers should always catch up with the current advances in the complex functions of Myc family in highly-malignant and heterogeneous tumor cells to realize the precision medicine.
                Bookmark

                Author and article information

                Contributors
                (+39) 049 8211312 , matteo.fassan@unipd.it
                luca.vianello.5@studenti.unipd.it
                diana.sacchi@studenti.unipd.it
                gnfanelli@gmail.com
                giadamunari@gmail.it
                marcoscarpa73@yahoo.it
                rocco.cappellesso@gmail.com
                fotios.loupakis@iov.veneto.it
                cristiano.lanza@unipd.it
                roberta.salmaso@unipd.it
                claudia.mescoli@libero.it
                nicola.valeri@icr.ac.uk
                m.agostini@unipd.it
                e.dangelo@irpcds.org
                sara.lonardi@iov.veneto.it
                puc@unipd.it
                ilmannato@gmail.com
                cladio.luchini@univr.it
                massimo.rugge@unipd.it
                Journal
                Cancer Cell Int
                Cancer Cell Int
                Cancer Cell International
                BioMed Central (London )
                1475-2867
                6 September 2018
                6 September 2018
                2018
                : 18
                : 131
                Affiliations
                [1 ]ISNI 0000 0004 1757 3470, GRID grid.5608.b, Surgical Pathology & Cytopathology Unit, Department of Medicine (DIMED), , University of Padua, ; via Gabelli 61, 35121 Padua, Italy
                [2 ]ISNI 0000 0004 1757 3470, GRID grid.5608.b, Department of Surgical Oncology and Gastroenterology (DiSCOG), , University of Padua, ; Padua, PD Italy
                [3 ]ISNI 0000 0004 1808 1697, GRID grid.419546.b, Unit of Oncology 1, Department of Clinical and Experimental Oncology, , Istituto Oncologico Veneto, IOV-IRCCS, ; Padua, PD Italy
                [4 ]ISNI 0000 0001 1271 4623, GRID grid.18886.3f, Division of Molecular Pathology, , The Institute of Cancer Research, ; Sutton, London, UK
                [5 ]ISNI 0000 0001 0304 893X, GRID grid.5072.0, Department of Medicine, , The Royal Marsden NHS Trust, ; Sutton, London, UK
                [6 ]ISNI 0000 0004 5907 2885, GRID grid.483819.f, Nanoinspired Biomedicine Laboratory, Institute of Pediatric Research, , Fondazione Città della Speranza, ; Padua, PD Italy
                [7 ]ISNI 0000 0004 0445 0041, GRID grid.63368.38, Department of Nanomedicine, , The Methodist Hospital Research Institute, ; Houston, TX USA
                [8 ]ISNI 0000 0001 1940 4177, GRID grid.5326.2, National Research Council, Neuroscience Institute, ; Aging Branch, Padua, PD Italy
                [9 ]ISNI 0000 0004 1756 948X, GRID grid.411475.2, Department of Diagnostics and Public Health, Section of Pathology, , University and Hospital Trust of Verona, ; Verona, VR Italy
                [10 ]Veneto Cancer Registry, Padua, PD Italy
                [11 ]National Institute of Gastroenterology-Research Hospital, IRCCS “S. de Bellis”, 70013 Castellana Grotte, BA Italy
                Author information
                http://orcid.org/0000-0001-6515-5482
                Article
                634
                10.1186/s12935-018-0634-8
                6127990
                63663f93-8230-4c3b-8371-0ff91a8370dc
                © The Author(s) 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 23 July 2018
                : 3 September 2018
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100005010, Associazione Italiana per la Ricerca sul Cancro;
                Award ID: AIRC Regional grant 2008 N. 6421
                Award Recipient :
                Categories
                Primary Research
                Custom metadata
                © The Author(s) 2018

                Oncology & Radiotherapy
                extranodal extension,metastasis,colorectal cancer,biomarkers
                Oncology & Radiotherapy
                extranodal extension, metastasis, colorectal cancer, biomarkers

                Comments

                Comment on this article